175 related articles for article (PubMed ID: 21747894)
21. Selective progesterone receptor modulators (SPRMs) for uterine fibroids.
Murji A; Whitaker L; Chow TL; Sobel ML
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD010770. PubMed ID: 28444736
[TBL] [Abstract][Full Text] [Related]
22. Preclinical investigations with mistletoe (Viscum album L.) extract Iscador.
Maldacker J
Arzneimittelforschung; 2006 Jun; 56(6A):497-507. PubMed ID: 16927531
[TBL] [Abstract][Full Text] [Related]
23. Mistletoe Preparation Iscador: Are there Methodological Concerns with Respect to Controlled Clinical Trials?
Ziegler R
Evid Based Complement Alternat Med; 2009 Mar; 6(1):19-30. PubMed ID: 18955241
[TBL] [Abstract][Full Text] [Related]
24. Retrolective, comparative, epidemiological cohort study with parallel groups design for evaluation of efficacy and safety of drugs with "well-established use".
Bock PR; Friedel WE; Hanisch J; Karasmann M; Schneider B
Forsch Komplementarmed Klass Naturheilkd; 2004 Aug; 11 Suppl 1():23-9. PubMed ID: 15353899
[TBL] [Abstract][Full Text] [Related]
25. Absence of tumor growth stimulation in a panel of 16 human tumor cell lines by mistletoe extracts in vitro.
Maier G; Fiebig HH
Anticancer Drugs; 2002 Apr; 13(4):373-9. PubMed ID: 11984083
[TBL] [Abstract][Full Text] [Related]
26. Voluntary counseling and testing (VCT) for changing HIV-related risk behavior in developing countries.
Fonner VA; Denison J; Kennedy CE; O'Reilly K; Sweat M
Cochrane Database Syst Rev; 2012 Sep; 9(9):CD001224. PubMed ID: 22972050
[TBL] [Abstract][Full Text] [Related]
27. [Efficacy and safety of long-term complementary treatment with standardized European mistletoe extract (Viscum album L.) in addition to the conventional adjuvant oncologic therapy in patients with primary non-metastasized mammary carcinoma. Results of a multi-center, comparative, epidemiological cohort study in Germany and Switzerland].
Bock PR; Friedel WE; Hanisch J; Karasmann M; Schneider B
Arzneimittelforschung; 2004; 54(8):456-66. PubMed ID: 15460213
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of mistletoe extract as a complement to standard treatment in advanced pancreatic cancer: study protocol for a multicentre, parallel group, double-blind, randomised, placebo-controlled clinical trial (MISTRAL).
Wode K; Hök Nordberg J; Kienle GS; Elander NO; Bernhardson BM; Sunde B; Sharp L; Henriksson R; Fransson P
Trials; 2020 Sep; 21(1):783. PubMed ID: 32917288
[TBL] [Abstract][Full Text] [Related]
29. Mistletoe in cancer - a systematic review on controlled clinical trials.
Kienle GS; Berrino F; Büssing A; Portalupi E; Rosenzweig S; Kiene H
Eur J Med Res; 2003 Mar; 8(3):109-19. PubMed ID: 12730032
[TBL] [Abstract][Full Text] [Related]
30. Systematic evaluation of the clinical effects of supportive mistletoe treatment within chemo- and/or radiotherapy protocols and long-term mistletoe application in nonmetastatic colorectal carcinoma: multicenter, controlled, observational cohort study.
Friedel WE; Matthes H; Bock PR; Zänker KS
J Soc Integr Oncol; 2009; 7(4):137-45. PubMed ID: 19883529
[TBL] [Abstract][Full Text] [Related]
31. Non-lectin component in a fermented extract from Viscum album L. grown on pines induces proliferation of lymphocytes from healthy and allergic individuals in vitro.
Stein G; Berg PA
Eur J Clin Pharmacol; 1994; 47(1):33-8. PubMed ID: 7988621
[TBL] [Abstract][Full Text] [Related]
32. Safety and efficacy of the long-term adjuvant treatment of primary intermediate- to high-risk malignant melanoma (UICC/AJCC stage II and III) with a standardized fermented European mistletoe (Viscum album L.) extract. Results from a multicenter, comparative, epidemiological cohort study in Germany and Switzerland.
Augustin M; Bock PR; Hanisch J; Karasmann M; Schneider B
Arzneimittelforschung; 2005; 55(1):38-49. PubMed ID: 15727163
[TBL] [Abstract][Full Text] [Related]
33. The effects of idarubicin versus other anthracyclines for induction therapy of patients with newly diagnosed leukaemia.
Li X; Xu S; Tan Y; Chen J
Cochrane Database Syst Rev; 2015 Jun; (6):CD010432. PubMed ID: 26037486
[TBL] [Abstract][Full Text] [Related]
34. Effects of a lectin- and a viscotoxin-rich mistletoe preparation on clinical and hematologic parameters: a placebo-controlled evaluation in healthy subjects.
Huber R; Klein R; Berg PA; Lüdtke R; Werner M
J Altern Complement Med; 2002 Dec; 8(6):857-66. PubMed ID: 12614536
[TBL] [Abstract][Full Text] [Related]
35. Anticarcinogenic and antimetastatic activity of Iscador.
Kuttan G; Menon LG; Antony S; Kuttan R
Anticancer Drugs; 1997 Apr; 8 Suppl 1():S15-6. PubMed ID: 9179361
[TBL] [Abstract][Full Text] [Related]
36. The effectiveness of therapeutic patient education on adherence to oral anti-cancer medicines in adult cancer patients in ambulatory care settings: a systematic review.
Arthurs G; Simpson J; Brown A; Kyaw O; Shyrier S; Concert CM
JBI Database System Rev Implement Rep; 2015 Jun; 13(5):244-92. PubMed ID: 26455611
[TBL] [Abstract][Full Text] [Related]
37. Effect of a mistletoe extract (Iscador QuFrF) on viability and migratory behavior of human peripheral CD4+ and CD8+ T lymphocytes in three-dimensional collagen lattices.
Nikolai G; Friedl P; Werner M; Niggemann B; Zänker KS
In Vitro Cell Dev Biol Anim; 1997 Oct; 33(9):710-6. PubMed ID: 9358287
[TBL] [Abstract][Full Text] [Related]
38. Cellular and humoral adjuvant activity of mistletoe extract.
Bloksma N; Van Dijk H; Korst P; Willers JM
Immunobiology; 1979 Sep; 156(3):309-18. PubMed ID: 575523
[TBL] [Abstract][Full Text] [Related]
39. Complementary cancer therapy: a systematic review of prospective clinical trials on anthroposophic mistletoe extracts.
Kienle GS; Kiene H
Eur J Med Res; 2007 Mar; 12(3):103-19. PubMed ID: 17507307
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
